199 related articles for article (PubMed ID: 26181166)
1. Using Somatic Mutations to Guide Treatment Decisions: Context Matters.
Horlings HM; Shah SP; Huntsman DG
JAMA Oncol; 2015 Jun; 1(3):275-6. PubMed ID: 26181166
[No Abstract] [Full Text] [Related]
2. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
3. Multigene Panel Testing in Oncology Practice: How Should We Respond?
Kurian AW; Ford JM
JAMA Oncol; 2015 Jun; 1(3):277-8. PubMed ID: 26181167
[No Abstract] [Full Text] [Related]
4. Gene Mutation Profiling of Breast Cancers for Clinical Decision Making: Drivers and Passengers in the Cart Before the Horse.
Stearns V; Park BH
JAMA Oncol; 2015 Aug; 1(5):569-70. PubMed ID: 26182336
[No Abstract] [Full Text] [Related]
5. Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.
Curiel-Olmo S; García-Castaño A; Vidal R; Pisonero H; Varela I; León-Castillo A; Trillo E; González-Vela C; García-Diaz N; Almaraz C; Moreno T; Cereceda L; Madureira R; Martinez N; Ortiz-Romero P; Valdizán E; Piris MA; Vaqué JP
Oncotarget; 2015 Sep; 6(28):25452-65. PubMed ID: 26327537
[TBL] [Abstract][Full Text] [Related]
6. Brave-ish New World--What's Needed to Make Precision Oncology a Practical Reality.
MacConaill LE; Lindeman NI; Rollins BJ
JAMA Oncol; 2015 Oct; 1(7):879-80. PubMed ID: 26181886
[No Abstract] [Full Text] [Related]
7. Detection of Chromosomal Abnormalities with Different In Situ Hybridisation Techniques--the Usefulness in the Qualification of Cancer Patients for Molecularly-Targeted Therapies.
Nicoś M; Wojas-Krawczyk K; Krawczyk P; Milanowski J
Adv Clin Exp Med; 2015; 24(4):715-23. PubMed ID: 26469118
[TBL] [Abstract][Full Text] [Related]
8. Anticipating designer drug-resistant cancer cells.
Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
[TBL] [Abstract][Full Text] [Related]
9. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
Farwell MD; Clark AS; Mankoff DA
JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
[No Abstract] [Full Text] [Related]
10. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer.
Dietrich MF; Collins RH; Gerber DE
JAMA Oncol; 2016 Jan; 2(1):132-3. PubMed ID: 26426250
[No Abstract] [Full Text] [Related]
13. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
14. Mutation and location important in cancer treatment.
Lewis R
Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321213
[No Abstract] [Full Text] [Related]
15. Lack of access to targeted cancer therapy.
Burki TK
Lancet Oncol; 2015 Oct; 16(13):e482. PubMed ID: 26321211
[No Abstract] [Full Text] [Related]
16. Advances in Molecular Pathology and Treatment of Periampullary Cancers.
Chandrasegaram MD; Chen JW; Price TJ; Zalcberg J; Sjoquist K; Merrett ND
Pancreas; 2016 Jan; 45(1):32-9. PubMed ID: 26348463
[TBL] [Abstract][Full Text] [Related]
17. What have we learned from exceptional tumour responses?: Review and perspectives.
Mehra N; Lorente D; de Bono JS
Curr Opin Oncol; 2015 May; 27(3):267-75. PubMed ID: 25811347
[TBL] [Abstract][Full Text] [Related]
18. Implications of intratumour heterogeneity for treatment stratification.
Crockford A; Jamal-Hanjani M; Hicks J; Swanton C
J Pathol; 2014 Jan; 232(2):264-73. PubMed ID: 24115146
[TBL] [Abstract][Full Text] [Related]
19. Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review.
Kadia TM; Ravandi F; Cortes J; Kantarjian H
JAMA Oncol; 2015 Sep; 1(6):820-8. PubMed ID: 26181162
[TBL] [Abstract][Full Text] [Related]
20. JAMA Oncology Patient Page. The Evolution of a Cancer.
West HJ; Jin JO
JAMA Oncol; 2015 Sep; 1(6):850. PubMed ID: 26247697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
